Physician profile
Daniel J Pollman
NPI 1487630950
$3,081.53
in general payments reported to CMS, 2019-2025
22 companies · $401 in 2025
The $401 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $680 · 2020: $116 · 2021: $233 · 2022: $564 · 2023: $558 · 2024: $529 · 2025: $401.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,488.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,488.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $952.17 | 2019-2025 | Trelegy Ellipta, Nucala |
| Boehringer Ingelheim Pharmaceuticals, INC. | $822.01 | 2019-2025 | Ofev, Jascayd |
| Astrazeneca Pharmaceuticals LP | $241.25 | 2020-2025 | Tezspire, Breztri, Airsupra |
| Regeneron Healthcare Solutions, INC. | $113.97 | 2021-2025 | Dupixent |
| Actelion Pharmaceuticals US, INC. | $106.67 | 2019-2023 | Opsumit, Uptravi |
| Philips North America LLC | $96.15 | 2019-2020 | |
| Mylan Specialty L.P. | $94.45 | 2020-2024 | Yupelri |
| Janssen Pharmaceuticals, INC | $87.94 | 2019 | |
| Electromed, INC. | $77.75 | 2019-2024 | Smartvest |
| Gilead Sciences, INC. | $60.23 | 2022 | |
| Sunovion Pharmaceuticals INC. | $56.72 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $52.80 | 2022-2024 | |
| Viatris Specialty LLC | $47.39 | 2025 | Yupelri |
| Genentech USA, INC. | $46.95 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $46.10 | 2023-2025 | Glassia, Takhzyro |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $40.33 | 2019-2022 | |
| Pulmonx Corporation | $38.34 | 2022-2023 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| Avadel Cns Pharmaceuticals, LLC | $24.13 | 2023 | Lumryz |
| Inogen, INC. | $21.14 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Insmed, INC. | $19.74 | 2024 | Arikayce |
| Grifols USA, LLC | $19.24 | 2024 | Xembify |
| Amgen INC. | $16.06 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Pollman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.